159 related articles for article (PubMed ID: 18836626)
1. Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic.
Voiculescu M; Winkler RE; Moscovici M; Neuman MG
J Gastrointestin Liver Dis; 2008 Sep; 17(3):315-22. PubMed ID: 18836626
[TBL] [Abstract][Full Text] [Related]
2. On the TRAIL to therapeutic intervention in liver disease.
Herr I; Schemmer P; Büchler MW
Hepatology; 2007 Jul; 46(1):266-74. PubMed ID: 17596886
[TBL] [Abstract][Full Text] [Related]
3. Steatosis: co-factor in other liver diseases.
Powell EE; Jonsson JR; Clouston AD
Hepatology; 2005 Jul; 42(1):5-13. PubMed ID: 15962320
[TBL] [Abstract][Full Text] [Related]
4. The journey from hepatitis to hepatocellular carcinoma. Bridging role of Helicobacter species.
Fagoonee S; Pellicano R; Rizzetto M; Ponzetto A
Panminerva Med; 2001 Dec; 43(4):279-82. PubMed ID: 11677423
[TBL] [Abstract][Full Text] [Related]
5. Role of alcohol in liver carcinogenesis.
McKillop IH; Schrum LW
Semin Liver Dis; 2009 May; 29(2):222-32. PubMed ID: 19387921
[TBL] [Abstract][Full Text] [Related]
6. New therapies for hepatocellular carcinoma.
Avila MA; Berasain C; Sangro B; Prieto J
Oncogene; 2006 Jun; 25(27):3866-84. PubMed ID: 16799628
[TBL] [Abstract][Full Text] [Related]
7. Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury.
Powell CL; Kosyk O; Bradford BU; Parker JS; Lobenhofer EK; Denda A; Uematsu F; Nakae D; Rusyn I
Hepatology; 2005 Nov; 42(5):1137-47. PubMed ID: 16250055
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapies in hepatocellular carcinoma.
Wörns MA; Weinmann A; Schuchmann M; Galle PR
Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
[TBL] [Abstract][Full Text] [Related]
9. The global impact of hepatic fibrosis and end-stage liver disease.
Lim YS; Kim WR
Clin Liver Dis; 2008 Nov; 12(4):733-46, vii. PubMed ID: 18984463
[TBL] [Abstract][Full Text] [Related]
10. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system.
Berasain C; Castillo J; Prieto J; Avila MA
Liver Int; 2007 Mar; 27(2):174-85. PubMed ID: 17311611
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
Zender L; Kubicka S
Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of hepatocellular carcinoma and molecular therapies.
Mínguez B; Tovar V; Chiang D; Villanueva A; Llovet JM
Curr Opin Gastroenterol; 2009 May; 25(3):186-94. PubMed ID: 19387255
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.
Kudo M
Oncology; 2008; 75 Suppl 1():1-12. PubMed ID: 19092266
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathogenesis of hepatocellular carcinoma.
McKillop IH; Moran DM; Jin X; Koniaris LG
J Surg Res; 2006 Nov; 136(1):125-35. PubMed ID: 17023002
[TBL] [Abstract][Full Text] [Related]
16. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy.
Perugorria MJ; Castillo J; Latasa MU; Goñi S; Segura V; Sangro B; Prieto J; Avila MA; Berasain C
Cancer Res; 2009 Feb; 69(4):1358-67. PubMed ID: 19190340
[TBL] [Abstract][Full Text] [Related]
17. [Hypoxia in hepatocellular carcinoma].
Myung SJ; Yoon JH
Korean J Hepatol; 2007 Mar; 13(1):9-19. PubMed ID: 17380070
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma associated with autoimmune hepatitis.
Nishiyama R; Kanai T; Abe J; Hara R; Watahiki Y; Sakaguchi T; Nakamura S
J Hepatobiliary Pancreat Surg; 2004; 11(3):215-9. PubMed ID: 15235898
[TBL] [Abstract][Full Text] [Related]
19. Prevention of hepatocellular carcinoma in nonviral-related liver diseases.
Fan JG; Farrell GC;
J Gastroenterol Hepatol; 2009 May; 24(5):712-9. PubMed ID: 19646014
[TBL] [Abstract][Full Text] [Related]
20. 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
Chuma M; Hige S; Nakanishi M; Ogawa K; Natsuizaka M; Yamamoto Y; Asaka M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1431-6. PubMed ID: 18854000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
